EP Patent

EP3539540B1 — Sglt2 inhibitor 1-chloro-4-(beta-d-glucopyranos-1-yl)-2-[4-((s)-tetrahydrofuran-3- yloxy)-benzyl]-benzene in combination with insulin for use in a method for reducing the risk of hypoglycemia

Assigned to Boehringer Ingelheim International GmbH · Expires 2024-12-18 · 1y expired

What this patent protects

Patent listed against Jardiance.

Drugs covered by this patent

Patent Metadata

Patent number
EP3539540B1
Jurisdiction
EP
Classification
—
Expires
2024-12-18
Drug substance claim
No
Drug product claim
No
Assignee
Boehringer Ingelheim International GmbH
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.